BR112015004696A2 - polipeptídeos quiméricos tendo especificidade de ligação alvejada - Google Patents

polipeptídeos quiméricos tendo especificidade de ligação alvejada

Info

Publication number
BR112015004696A2
BR112015004696A2 BR112015004696A BR112015004696A BR112015004696A2 BR 112015004696 A2 BR112015004696 A2 BR 112015004696A2 BR 112015004696 A BR112015004696 A BR 112015004696A BR 112015004696 A BR112015004696 A BR 112015004696A BR 112015004696 A2 BR112015004696 A2 BR 112015004696A2
Authority
BR
Brazil
Prior art keywords
chimeric polypeptides
methods
compositions
binding specificity
targeted binding
Prior art date
Application number
BR112015004696A
Other languages
English (en)
Other versions
BR112015004696B1 (pt
Inventor
Mercer Andrew
M Lamb Brian
F Barbas Carlos Iii
Gaj Thomas
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR112015004696A2 publication Critical patent/BR112015004696A2/pt
Publication of BR112015004696B1 publication Critical patent/BR112015004696B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Abstract

abstract disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. the compositions, vectors, and methods of the present invention are also useful in gene therapy techniques. the invention provides a chimeric polypeptide. the polypeptide includes: a) a recombinase, nuclease or transcription factor, or fragment thereof; and b) a transcription activator-like effector (tale) protein. tradução do resumo resumo patente de invenção: "polipeptídeos quiméricos tendo especificidade de ligação alvejada" a presente invenção refere-se aos polipeptídeos quiméricos descritos aqui, incluindo suas composições, vetores de expressão, e métodos de seu uso, para a geração de células transgênicas, tecidos, plantas, e animais. as composições, vetores, e métodos da presente invenção também são úteis nas técnicas
BR112015004696-7A 2012-09-04 2013-09-04 Polipeptídeos quiméricos tendo especificidade de ligação direcionada, método de geração de um domínio n-terminal (ntd) de proteína efetora tipo ativador de transcrição (tale) e método para a recombinação sítio-específica BR112015004696B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261696689P 2012-09-04 2012-09-04
US61/696,689 2012-09-04
US201361753763P 2013-01-17 2013-01-17
US61/753,763 2013-01-17
US201361818364P 2013-05-01 2013-05-01
US61/818,364 2013-05-01
PCT/US2013/058100 WO2014039585A2 (en) 2012-09-04 2013-09-04 Chimeric polypeptides having targeted binding specificity

Publications (2)

Publication Number Publication Date
BR112015004696A2 true BR112015004696A2 (pt) 2017-11-21
BR112015004696B1 BR112015004696B1 (pt) 2022-07-19

Family

ID=50237752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004696-7A BR112015004696B1 (pt) 2012-09-04 2013-09-04 Polipeptídeos quiméricos tendo especificidade de ligação direcionada, método de geração de um domínio n-terminal (ntd) de proteína efetora tipo ativador de transcrição (tale) e método para a recombinação sítio-específica

Country Status (12)

Country Link
US (4) US9902962B2 (pt)
EP (3) EP2893022B1 (pt)
JP (4) JP6442406B2 (pt)
KR (3) KR102357105B1 (pt)
CN (2) CN104781404B (pt)
AU (3) AU2013312801B2 (pt)
BR (1) BR112015004696B1 (pt)
CA (1) CA2883511A1 (pt)
DK (1) DK2893022T3 (pt)
IL (1) IL237442B (pt)
SG (2) SG10201701675PA (pt)
WO (1) WO2014039585A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199630B1 (en) 2008-09-05 2019-05-08 President and Fellows of Harvard College Continuous directed evolution of proteins and nucleic acids
WO2012088381A2 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
US9902962B2 (en) 2012-09-04 2018-02-27 The Scripps Research Institute Chimeric polypeptides having targeted binding specificity
US9708589B2 (en) * 2012-12-18 2017-07-18 Monsanto Technology Llc Compositions and methods for custom site-specific DNA recombinases
US10793867B2 (en) 2013-03-15 2020-10-06 Monsanto Technology, Llc Methods for targeted transgene-integration using custom site-specific DNA recombinases
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10507232B2 (en) 2014-04-02 2019-12-17 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
JP6796773B2 (ja) 2014-07-30 2020-12-09 ツムトー バイオロジクス、インコーポレイテッド 非フコシル化タンパク質および方法
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2017015545A1 (en) * 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
WO2017031483A1 (en) * 2015-08-20 2017-02-23 Applied Stemcell, Inc. Nuclease with enhanced efficiency of genome editing
WO2017070633A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
EP3497214B1 (en) * 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3039928A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018187796A1 (en) * 2017-04-07 2018-10-11 Donald Danforth Plant Science Center Methods for increasing resistance to cotton bacterial blight and plants produced thereby
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College EVOLUTION OF ARNT SYNTHÉTASES
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
CN109771403A (zh) * 2019-01-24 2019-05-21 广州医科大学附属第一医院 一种大鼠造影剂肾病模型的构建方法
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
TW202132565A (zh) * 2019-11-01 2021-09-01 美商聖加莫治療股份有限公司 Ｇｉｎ重組酶變異體
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
WO2022016118A2 (en) * 2020-07-17 2022-01-20 Cb Therapeutics, Inc. Prenyltransferase enzymes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2137547A1 (en) * 1992-06-11 1993-12-23 Daniel Meruelo Chimeric receptor polypeptides, human h13 proteins and uses thereof
US20050084885A1 (en) 1994-01-18 2005-04-21 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
WO2000073434A1 (en) 1999-05-28 2000-12-07 Sangamo Biosciences, Inc. Gene switches
US7277941B2 (en) 1998-03-11 2007-10-02 Commvault Systems, Inc. System and method for providing encryption in a storage network by storing a secured encryption key with encrypted archive data in an archive storage device
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
DE60023936T2 (de) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2002241946B2 (en) 2001-01-22 2007-04-26 Sangamo Therapeutics, Inc. Modified zinc finger binding proteins
US7067617B2 (en) 2001-02-21 2006-06-27 The Scripps Research Institute Zinc finger binding domains for nucleotide sequence ANN
EP1421177A4 (en) 2001-08-20 2006-06-07 Scripps Research Inst ZINC FINGER FASTENING DOMAINS FOR CNN
EP1481087A4 (en) 2002-02-07 2005-12-21 Scripps Research Inst ZINC FINGER LIBRARIES
US20060211846A1 (en) 2002-02-13 2006-09-21 Barbas Carlos F Iii Zinc finger binding domains for nucleotide sequence ANN
KR20090031938A (ko) * 2006-07-05 2009-03-30 더 스크립스 리서치 인스티튜트 방향성 진화로 촉매 작용을 최적화시킨 키메라 징크 핑거 리컴비나제
PL2510096T5 (pl) 2009-12-10 2018-06-29 Regents Of The University Of Minnesota Modyfikacja DNA zależna od efektora TAL
AU2011256838B2 (en) * 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9650647B2 (en) * 2010-09-06 2017-05-16 Temasek Life Sciences Laboratory Limited Molecular interaction between XA10 and AVRXA10
US9499592B2 (en) * 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
US9458205B2 (en) * 2011-11-16 2016-10-04 Sangamo Biosciences, Inc. Modified DNA-binding proteins and uses thereof
US9688997B2 (en) * 2011-12-29 2017-06-27 Iowa State University Research Foundation, Inc. Genetically modified plants with resistance to Xanthomonas and other bacterial plant pathogens
US9902962B2 (en) 2012-09-04 2018-02-27 The Scripps Research Institute Chimeric polypeptides having targeted binding specificity

Also Published As

Publication number Publication date
WO2014039585A2 (en) 2014-03-13
CN109517068A (zh) 2019-03-26
BR112015004696B1 (pt) 2022-07-19
KR20220016303A (ko) 2022-02-08
EP4148134A1 (en) 2023-03-15
WO2014039585A3 (en) 2014-05-22
IL237442B (en) 2019-11-28
KR102596125B1 (ko) 2023-10-30
KR102357105B1 (ko) 2022-02-08
US10829766B2 (en) 2020-11-10
CN104781404A (zh) 2015-07-15
CN104781404B (zh) 2018-10-26
AU2019200922B2 (en) 2021-07-08
JP7459174B2 (ja) 2024-04-01
DK2893022T3 (da) 2020-07-27
AU2013312801A1 (en) 2015-03-26
EP3750999B1 (en) 2022-06-29
US20230304022A1 (en) 2023-09-28
EP2893022A4 (en) 2016-03-02
US20150284728A1 (en) 2015-10-08
IL237442A0 (en) 2015-04-30
AU2021240252A1 (en) 2021-10-28
US11466277B2 (en) 2022-10-11
CN109517068B (zh) 2023-07-25
KR20150070120A (ko) 2015-06-24
JP6442406B2 (ja) 2018-12-19
EP2893022B1 (en) 2020-05-13
JP6728283B2 (ja) 2020-07-22
US20180230474A1 (en) 2018-08-16
AU2013312801B2 (en) 2018-11-15
US20210147854A1 (en) 2021-05-20
KR102201867B1 (ko) 2021-01-12
JP2022130649A (ja) 2022-09-06
SG10201701675PA (en) 2017-04-27
US9902962B2 (en) 2018-02-27
EP3750999A1 (en) 2020-12-16
SG11201501525QA (en) 2015-03-30
CA2883511A1 (en) 2014-03-13
JP2018183180A (ja) 2018-11-22
AU2019200922A1 (en) 2019-02-28
KR20210008437A (ko) 2021-01-21
JP2015532654A (ja) 2015-11-12
EP2893022A2 (en) 2015-07-15
JP7100681B2 (ja) 2022-07-13
JP2020178703A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
BR112015004696A2 (pt) polipeptídeos quiméricos tendo especificidade de ligação alvejada
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
CY1119283T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
BR112015020885A2 (pt) polipeptídeos de ligação hiperglicosilados
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
TN2015000177A1 (en) Anti-ceacam5 antibodies and uses thereof
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
MX2014000054A (es) Moleculas de union anti-alfa sinucleina.
EA201200515A1 (ru) Полипептиды и их применение
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
BR112014019901A8 (pt) Proteínas de fator viii recombinante
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
MX2014012977A (es) Anticuerpos anti-cd22.
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112013009083A8 (pt) anticorpos humanos de oncostatin m e métodos de uso
PH12018501317A1 (en) Compositions and methods for efficient targeting of transgenes
UA117349C2 (uk) Одноланцюговий гібридний білок та спосіб лікування, попередження або усунення болю
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
BR112014002173A2 (pt) proteínas purificadas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2013, OBSERVADAS AS CONDICOES LEGAIS